STAT Plus: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share
Biosimilars
Biosimilars are cheaper versions of biologic drugs. They are approved by the FDA and can be used to treat a variety of diseases, including cancer and autoimmune disorders. Recent stories explore their potential cost-savings, regulatory issues and barriers to adoption.
Latest
STAT Plus: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market
STAT Plus: Virtual Event: March of the Biosimilars
STAT Plus: Here’s what you might have missed in Biden’s budget proposal
STAT readers on what human health care can learn from veterinary medicine and more
STAT Plus: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira
STAT Plus: The problem with potential changes to the biosimilar regulatory framework
STAT Plus: STAT Virtual Event: The State of Biosimilars: What to Watch
All Coverage
advertisement
